BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNT...

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)...

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)

BioNTech SE ( ($BNTX) ) has fallen by -9.52%. Read on to learn why. BioNTech SE shares fell 9.52% over the past week, even as the company signaled ...

BioNTech SE Slides as Bold HIV Bet Takes Shape

The latest update is out from BioNTech SE ( ($BNTX) ). Pfizer and BioNTech announced on August 27, 2026 that the U.S. Food and Drug Administration ...

BioNTech and Pfizer Secure FDA Nod for XFG-Adapted 2026–2027 COVID-19 Vaccine

Biontech Se Sponsored Adr ($BNTX) announced an update on their ongoing clinical study. The study, officially titled “A Randomized, Placebo-controll...

BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now

BioNTech SE ( ($BNTX) ) has provided an announcement. BioNTech SE reported on August 20, 2026, that it will present new clinical data from its lung...

BioNTech to Unveil Novel Lung Cancer Combination Data at WCLC 2026

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX) and Centene (CNC). BioNTech SE ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioNTech SE (BNTX) and Centene (CNC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xeris Pharmaceuticals (XERS) and BioNTech SE (BNTX) ...

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and BioNTech SE (BNTX)

Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatme...

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE, with a price target of $115.00. According to ...

BioNTech SE (BNTX) Receives a Buy from Morgan Stanley

Pfizer Inc ($PFE), Biontech Se Sponsored Adr ($BNTX) announced an update on their ongoing clinical study. The new phase 4 study from BioNTech SE an...

Pfizer and BioNTech Advance Variant-Adapted COVID-19 Booster in New Phase 4 Study

Pfizer Inc ($PFE), Biontech Se Sponsored Adr ($BNTX) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) and BioNTech SE (BNTX) ...

Pfizer and BioNTech Advance Next‑Season Pediatric COVID‑19 Booster Strategy With New Phase 3 Update

Wells Fargo analyst maintained a Buy rating on BioNTech SE today and set a price target of $140.00. In addition to Wells Fargo, BioNTech SE also re...

Wells Fargo Remains a Buy on BioNTech SE (BNTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX), BioNTech SE (BNTX) an...

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), BioNTech SE (BNTX) and Henry Schein (HSIC)

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE today and set a price target of $138.00. According to TipRanks, Tewari is a 5...

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Bernstein analyst Jeffrey Walch maintained a Hold rating on BioNTech SE today and set a price target of $96.00. According to TipRanks, Walch is a 3...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BNTX	$103.34	+0.45%	71.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BNTX	$103.34	+0.4%	71.27K
3
4
5
6

BNTX

Get BioNTech SE Data in Excel

Get BioNTech SE Data in Excel